Completed PHASE1 INTERVENTIONAL 2-arm NCT05354752

Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy Subjects

Randomized, Double-blind, Multiple-dose Escalation, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Pharmacodynamics of VC005 Tablets in Healthy Subjects

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

Conditions Inflammatory Bowel Diseases

Interventions VC005 Placebo tablets VC005 tablets

Updated 6 times since 2022 Last updated: Nov 16, 2022 Started: Jun 18, 2022 Primary completion: Nov 2, 2022 Completion: Nov 15, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Inflammatory Bowel Diseases, this trial is completed. The trial is conducted by Jiangsu vcare pharmaceutical technology co., LTD and has accumulated 6 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE1
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

May 2022 — Jul 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu vcare pharmaceutical technology co., LTD

Data source: Jiangsu vcare pharmaceutical technology co., LTD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changchun, China